Women with PMOS should get subsidised weight loss drugs, advocates say
With GLP-1s to treat the condition not specifically approved by the TGA, patients are being prescribed them off-label Get our breaking news email , free app or daily news podcast Women living with a chronic hormonal condition should have access to taxpayer-funded weight loss medications, advocates say. The Polyendrocrine Metabolic Ovarian Syndrome Association of Australia (POSAA) is urging for…
Women with Polycystic Ovary Syndrome (PCOS), also referred to as Polyendrocrine Metabolic Ovarian Syndrome, are advocating for access to subsidized weight loss medications. The Polyendrocrine Metabolic Ovarian Syndrome Association of Australia (POSAA) is pushing for GLP-1 drugs to be included on the Pharmaceutical Benefits Scheme for individuals with this condition.
Currently, GLP-1 drugs used to treat PCOS are not specifically approved by the Therapeutic Goods Administration (TGA) for this purpose, resulting in off-label prescriptions for patients. According to The Guardian Australia and The Guardian, advocates believe that making these medications available through the Pharmaceutical Benefits Scheme would provide necessary support for women managing the condition.
The condition, PCOS or Polyendrocrine Metabolic Ovarian Syndrome, is a chronic hormonal disorder that affects women. POSAA's advocacy aims to improve treatment options for those affected.
Brief written by urgent.news from The Guardian Australia, The Guardian — 2 reports on this story. Machine-written — may contain errors; check the original before relying on it.
